Current clinicopathologic staging systems and serum biomarkers poorly discriminate tumor biology in hepatocellular carcinoma (HCC), with high recurrence rates following curative-intent surgical resection and liver transplantation (LT). Identification of accurate biomarkers for improved prognostication and treatment selection is a critical unmet need. We sought to develop a novel "liquid-biopsy" assay capable of detecting HCC circulating tumor cells (CTCs) and characterizing phenotypic subpopulations with prognostic significance. Using HCC cell lines, a tissue microarray, and human blood samples, an antibody cocktail targeting the cell-surface markers asialoglycoprotein receptor (ASGPR), glypican-3, and epithelial cell adhesion molecule was optimized for HCC CTC capture using the NanoVelcro CTC Assay. The ability of HCC CTCs and vimentin (VIM)-positive CTCs (a subpopulation expressing an epithelial-to-mesenchymal phenotype) to accurately discriminate tumor stage, recurrence, progression, and overall survival (OS) was evaluated in a prospective study of 80 patients. Multimarker capture detected greater numbers of CTCs than any individual antibody alone for both cell line and patient samples (P < 0.001). HCC CTCs were identified in 59/61 (97%) patients, and HCC (median, 6 CTCs) and non-HCC patients (median, 1 CTC; area under the receiver operating characteristic curve [AUROC] 5 0.92; P < 0.001; sensitivity 5 84.2%; specificity 5 88.5%) were accurately discriminated. VIM-positive CTCs accurately discriminated early-stage, LT eligible patients (median, 0 CTCs) from locally advanced/metastatic, LT ineligible patients (median, 6 CTCs; AUROC 5 0.89; P 5 0.001; sensitivity 5 87.1%; specificity 5 90.0%), and predicted OS for all patients (hazard ratio [HR], 2.21; P 5 0.001), and faster recurrence after curative-intent surgical or locoregional therapy in potentially curable early-stage HCC (HR, 3.14; P 5 0.002). In conclusion, we developed a novel multimarker CTC enrichment assay that detects HCC CTCs with high efficiency and accuracy. A phenotypic subpopulation of VIM-positive CTCs appears to signify the presence of aggressive underlying disease and occult metastases and may have important implications for treatment selection.
detected in the peripheral blood, and are implicated as a potential cause of postsurgical recurrence and metastases. (4, 5) Although CTCs can serve as prognostic biomarkers in solid tumors, studies evaluating CTCs in HCC have found limited utility. (6, 7) One reason is that most CTC enrichment assays, including the US Food and Drug Administration-approved CellSearch CTC Assay, rely on the use of antibodies against the epithelial cell surface marker called epithelial cell adhesion molecule (EpCAM) to "capture" CTCs by antigen-specific immunomagnetic separation from leukocytes. Because only 20%-35% of HCCs express EpCAM, methods based on EpCAM alone have resulted in low CTC detection rates and limited utility for HCC. (8) Alternative CTC capture methods using antibodies directed at hepatocyte-specific cell surface markers, (7, 9) CD45 depletion, (10) or microfluidic (11) systems have all demonstrated increased efficiency in isolating HCC CTCs. Furthermore, these nonEpCAM-based methods allow for the capture of distinct CTC subpopulations with more mesenchymal properties in HCC. (9, 12) The identification and significance of CTC subpopulations expressing a mesenchymal phenotype is an area of active investigation in many solid tumors due to their potential role in metastasis. (13) Previous studies in HCC have demonstrated that epithelial-tomesenchymal transition (EMT), associated with losing expression of cell-cell adhesion markers and gaining the migratory and invasive properties of a mesenchymal cell, is an important step in the metastatic cascade. (14) Several studies in HCC have demonstrated that the overexpression of mesenchymal markers such as vimentin (VIM), an intermediate filament, is associated with more advanced tumors and worse prognosis. (15, 16) Thus, identifying CTCs that demonstrate an EMT phenotype holds promise for identifying patients likely to harbor aggressive underlying disease.
In this study, we investigated the use of a microfluidic, antibody-based CTC capture assay to efficiently capture HCC CTCs and characterize CTC phenotypes of prognostic importance. Unlike existing technologies, the NanoVelcro CTC Assay combines a microfluidic system with enhanced topographic interactions and CTC-capture antibody-coated nanostructured substrates to allow for the efficient separation and capture of HCC CTCs from background white blood cells (WBCs). The working principle of the NanoVelcro CTC Assay has been used for many solid tumors, including prostate cancer, melanoma, and pancreatic cancer. (17, 18) To optimize the use of the NanoVelcro CTC Assay for detecting HCC CTCs from patient blood, we investigated HCC CTC capture and immunostaining antibodies (7, 19) followed by validation of their efficacy using a HCC tissue microarray (TMA), HCC cell lines, and a pilot group of HCC patients. Subsequently, using this optimized assay in a prospective study of patients with nonmalignant liver disease (NMLD), HCC patients, and healthy controls without HCC or other identified liver disease, we did the following: 
Patients and Methods

ANTIBODY SELECTION FOR THE CAPTURE AND IDENTIFICATION OF HCC CTCs
The capture of CTCs relies on the antigen-specific immobilization of CTCs on the NanoVelcro surface using antibodies directed against HCC cell surface markers. Immobilized CTCs are then identified and phenotyped based on their immunohistochemical staining characteristics (Supporting Fig. 1) . A wide selection of antibodies for both CTC capture, as well as CTC identification and phenotyping, were evaluated using an 8 HCC cell line panel as detailed in the Supporting Information. Antibodies demonstrating optimal staining and specificity across the cell line panel were then tested for suitability on a 114-patient HCC TMA generated from archived, resected HCC specimens at the University of California, Los Angeles. (20) Antibodies against the cell surface markers EpCAM (Cell Signaling, Danvers, MA), asialoglycoprotein receptor (ASGPR; Abcam, Cambridge, UK), and glypican-3 (GPC-3; Santa Cruz Biotechnology, Santa Cruz, CA), as well as the cytoplasmic marker VIM (Abcam), were used to stain the TMA (Supporting Fig. 2 ). Staining intensity was assessed on a 4-point scale (none/weak/moderate/strong staining) by a single pathologist (S.W.F.), and tumors were considered to have stained positive if they displayed moderate or strong staining to any one of the antibodies tested (Supporting Fig. 3 ). TMA staining results were summarized as shown in Fig. 1A .
OPTIMIZATION OF MULTIMARKER CTC CAPTURE
The NanoVelcro CTC Assay uses a microfluidic chaotic mixer to enhance CTC interactions with the capture antibody coated nanosubstrate surface of the chip to enhance CTC capture rates (Supporting Fig. 1A) . Following CTC capture, CTCs are immunostained as outlined in our workflow (Supporting Fig. 1B ) and then identified and phenotyped using multicolor immunocytochemistry (ICC) and cytometric assessment (Supporting Figs. 4 and 5) . Although the performance of the NanoVelcro CTC Assay has been reported for many solid tumors, we first validated the methodology for HCC using cell lines as previously described and detailed in the Supporting Information. (21) All experiments were performed at the optimum flow rate of 1 mL per hour (Supporting Fig.  6A ). Calibration experiments using both HCC cell lines (Fig. 1B,C (24) SAMPLE PROCESSING, CHIP SCANNING, AND CTC ENUMERATION Blood samples were processed as previously described and detailed in the Supporting Information using the parameters determined by the optimization experiments described above. Captured CTCs were imaged using ICC, allowing for both cytometric and immunofluorescent identification parameters, and criteria for CTC identification were developed by a trained 0 ,6-diamidino-2-phenylindole (DAPI) 1/CD451/cytokeratin (CK) -, with size 6 lm; and HCC CTCs were defined as round/ovoid cells, DAPI1/CD45-/CK1, with size 6 lm. EMT phenotype, VIM-positive CTCs are the subpopulation of HCC CTCs defined as round/ovoid events, DAPI1/CD45-/CK1/VIM1, with size 6 lm. Any CD45 positivity >23 background discounted a cell as being a CTC. CTCs were enumerated by the same blinded researcher (S.H.), and CTC counts are represented as a total count per 4 mL venous blood (VB) (Fig. 2B ).
STATISTICAL METHODS
Continuous variables were summarized as median and interquartile range (IQR) and compared using the Wilcoxon rank sum test, whereas categorical variables were summarized as frequencies and percentages and compared using the v 2 test/Fisher's exact test. A 2-tailed P value < 0.05 was considered to be statistically significant. Differences in staining efficiency and CTC capture for different markers were compared using the Wilcoxon matched pairs signed rank test. CTC enumeration was reported per 4 mL of blood except as otherwise noted and compared among groups using the nonparametric Mann-Whitney U test. Cutoff points for CTC enumeration were evaluated using Youden's J statistic and using the cutoff finder web application. (25) Diagnostic performance of CTCs was COURT ET AL. LIVER TRANSPLANTATION, July 2018 evaluated using receiver operating characteristic (ROC) curves for determination of the area under the receiver operating characteristic curve (AUROC) in addition to sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) calculations. Outlier analysis was performed with the Iterative Grubb's method (a 5 0.05). Outlier analysis did not result in any changes in the statistical interpretation of the results (data not shown). Both CTC counts and AFP values had a skewed distribution and were log transformed. Posttransplant patients without a pretransplant blood draw were not included in the survival analysis (n 5 1). Overall survival (OS) was the time from initial blood draw (study enrollment) to last follow-up or death, with only death counting as an event. Progression-free survival (PFS) was evaluated only in the subset of advanced stage, incurable patients, with progression defined as measurable radiographic increase in tumor burden (measured by mRECIST) and measured from time of study enrollment to first radiographic progression or cancerrelated death. Time to recurrence (TTR) was evaluated only in the subset of early stage, potentially curable patients undergoing curative intent surgical or locoregional therapy, where the initial posttreatment imaging showed no viable arterially enhancing lesions (regardless of surgical resection, ablation, or in select cases, transcatheter arterial chemoembolization [TACE] treatment). Recurrence was defined as a new or recurrent radiographic lesion meeting Organ Procurement and Transplantation Network criteria for HCC. TTR of radiographically evident disease, PFS, and OS were computed using Kaplan-Meier methods and compared by the log-rank (Mantel-Cox) test.
Univariate analysis of individual predictors of PFS and TTR was performed using the Fine and Gray competing risks Cox regression model to account for the competing risk of non-HCC-related mortality. Factors identified as significant (P < 0.2) on univariate analysis were entered into a multivariate competing risk Cox regression model to identify significant independent predictors of HCC progression and recurrence. Hazard ratios (HRs) and 95% confidence intervals (CIs) were reported, and statistical significance was assessed based on nonoverlapping 95% CIs. For multivariate analysis, final models for OS, PFS, and TTR included AFP, UCSF staging, and primary tumor size, in addition to CTC count for both HCC CTCs and the subpopulation of VIM-positive CTCs. The HRs reported are per standard deviation increase of the CTC count on the log-scale. All statistical analyses and calculations were performed with the assistance of GraphPad Prism 7.0a (GraphPad Software, La Jolla, CA) and SAS (SAS Institute, Cary, NC), and follow the Reporting Recommendations for Tumor Marker Prognostic Studies guidelines. (26) Results
ANTIBODY SELECTION FOR THE CAPTURE AND IDENTIFICATION OF HCC CTCs
CTCs are first incubated with biotinylated antibody cocktail (EpCAM, ASGPR, and GPC-3) and then "captured" by the NanoVelcro CTC Assay through the interaction of biotin on the CTCs with the streptavidin-coated surface of the NanoVelcro chips. To optimize CTC capture, we used a TMA developed from 114 resected human HCC samples to screen the potential HCC-specific cell surface capture markers ASGPR and GPC-3, in addition to the widely used cell surface marker EpCAM. Of the 114 tumors, 89 (78.1%) stained for at least 1/3 antibodies (ASGPR, 65.8%; GPC-3, 31.6%; EpCAM, 7.9%; Fig. 1A) . However, the combination of all 3 antibodies stained significantly more tumors than any single antibody alone for the entire TMA, with staining of any 1 or more of the antibodies considered positive (P < 0.001 for ASGPR alone and P < 0.001 for EpCAM or GPC-3 alone).
OPTIMIZATION OF THE NANOVELCRO CTC ASSAY UTILIZING MULTIMARKER CTC CAPTURE
Capture Antibody Optimization in HCC Cell Lines
Using artificial blood samples consisting of 500 HCC cell line cells spiked in 2-mL normal blood samples, the CTC capture efficiency for each individual capture antibody (EpCAM, ASGPR, and GPC-3) was compared with the combination of all 3 antibodies for 8 HCC cell lines (Fig. 1B) . Use of the triple-antibody multimarker capture cocktail resulted in the highest CTC capture efficiency (>80%), significantly greater than any single capture antibody alone (P 5 0.02 for EpCAM; P < 0.001 for ASGPR and GPC-3; Fig. 1C ).
Capture Antibody Optimization in Human HCC Patients
In a preliminary cohort of 10 patients with HCC, we evaluated the total CTCs enumerated using EpCAM alone, ASGPR alone, GPC-3 alone, and the triple multimarker antibody cocktail (Fig. 1D) . Similar to our cell line results, we found that the combination of all 3 capture antibodies resulted in significantly greater CTCs captured compared with the use of any single antibody alone (versus multimarker capture, P 5 0.04 for EpCAM; P 5 0.007 for ASGPR; and P 5 0.007 for GPC-3; Fig. 1E ).
Defining HCC CTC Phenotypes
To ensure that our immunocytochemical staining of HCC CTCs was specific for hepatocytes, selected patient samples were stained with CK as the primary epithelial marker, and costained with hepatocytespecific markers AFP, arginase, and hep-par-1. AFP, arginase, and hep-par-1 staining was only noted in the cytokeratin (CK)-positive cells and never in the CD45-positive leukocytes, confirming the specificity of our ICC criteria for HCC CTCs (Supporting Fig. 5 ).
Additionally, we discovered a subpopulation of VIMpositive CTCs with an epithelial-to-mesenchymal phenotype. On the basis of these initial experiments, all prospective HCC patients enrolled in the study underwent enumeration of HCC CTCs and the subpopulation of VIM-positive CTCs (Fig. 2) .
PROSPECTIVE STUDY EVALUATING CTC ENUMERATION AND PHENOTYPE UTILIZING OPTIMIZED MULTIMARKER HCC NANOVELCRO ASSAY
Of 84 patients approached for study participation, 80 patients underwent peripheral blood draw, CTC enumeration, and phenotyping using our optimized multimarker NanoVelcro HCC CTC Assay (Table 1) . Four patients were excluded (2 refused informed consent; 1 had synchronous cancer; and 1 had insufficient blood draw). Of the 80 enrolled patients, 61 had HCC, 11 had NMLD (7 with cirrhosis without HCC; 4 with benign liver lesions), and 8 were healthy controls (Fig.  3 ). Among patients with HCC, 31/61 (50.8%) were early stage (within UCSF transplant eligibility criteria), (23) 21/61 (34.4%) were locally advanced with extensive liver involvement, and 9/61 (14.8%) were metastatic. Overall, 41% of enrolled patients received prior systemic or locoregional therapy (median, 124 days; range, 23-235 days prior to blood draw). Patients were followed for a median of 325 days after blood draw. Of the 61 patients with HCC, 28 (45.9%) NOTE: Data are given as n (%) or median (IQR). *For the percentage value, n 5 61. **For percentage value, n 5 25 receiving predraw treatment.
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progressed and 20 (32.8%) died. Patients with NMLD were followed for an equivalent amount of time. None of the NMLD or healthy control patients involved in the study developed HCC during follow-up.
HCC CTCs
HCC CTCs were found in 59/61 (96.7%) patients with HCC (median, 6; range, 0-23). Occasional patients with NMLD were found to have low numbers of CTCs (median, 1; range, 0-7), particularly those with inflammatory adenomas (Fig. 2B) . A single CTC was found in 2/8 (25%) healthy control patients, indicating a false positive. Among patients with HCC, CTC count correlated with stage, with a median of 3 CTCs in early-stage patients (range, 0-15), 9 CTCs in locally advanced HCC (range, 0-14), and 12 CTCs in patients with metastatic HCC (range, 2-23; Fig. 3 ). Significantly more HCC CTCs were found in patients with radiographic evidence of portal vein invasion (P 5 0.001).
At the optimum cutoff of 2 CTCs/4 mL VB, HCC CTC enumeration accurately discriminated among patients with and without HCC (NMLD or healthy controls) with a sensitivity 5 84.2%, specificity 5 88.5%, PPV 5 69.6%, NPV 5 94.7% (Fig.  4A ) and an AUROC of 0.92 (95% CI, 0.86-0.99; P < 0.001), illustrating the ability of CTCs to discriminate patients with cancer from those without (Fig. 4B) . A similar discriminatory performance was found when HCC patients were compared with NMLD alone (AUROC 5 0.89).
Univariate Cox analysis of all HCC patients revealed that HCC CTCs were associated with worse OS (HR, 1.96; 95% CI, 1.12-3.42; P 5 0.02). In the subset of nonmetastatic, potentially curable patients (n 5 30) who underwent locoregional therapy (resection, n 5 9; transplantation, n 5 5; radiofrequency ablation [RFA], n 5 11; or TACE, n 5 5), HCC CTCs were associated with faster TTR (HR, 9.7; 95% CI, 2.08-45.19; P 5 0.004). In patients with incurable, locally advanced (n 5 15, diffuse infiltration or macrovascular invasion) or metastatic disease (n 5 8), HCC CTCs were associated with worse PFS (HR, 2.09; 95% CI, 1.11-3.96; P 5 0.02). On multivariate analysis, including the covariates age, AFP, Model for EndStage Liver Disease (MELD) score, and tumor size, HCC CTCs were again found to be significantly associated with PFS (HR, 2.09; 95% CI, 1.11-3.96; P 5 0.02) in the subset of advanced-stage patients but not TTR in potentially curable early-stage patients or OS in all patients. Univariate analysis of all HCC patients revealed that VIM-positive CTCs were highly associated with inferior OS (HR, 2.21; 95% CI, 1.38-3.52; P 5 0.001; Fig. 5A ). Perhaps more notably, CTCs were able to discriminate outcomes in the subset of potentially curable patients undergoing locoregional therapy (resection, n 5 9; transplantation, n 5 5; RFA, n 5 11, and TACE, n 5 5). In this subset of 30 patients who radiographically demonstrated no residual disease following treatment, the presence of any pretreatment VIM-positive CTCs were associated with faster TTR (HR, 3.14; 95% CI, 1.50-6.57; P 5 0.002; Fig. 5B) . Similarly, in the subset of incurable locally advanced or metastatic patients (n 5 23), VIM-positive CTCs were predictive of worse PFS (HR, 1.81; 95% CI, 1.02-3.22; P 5 0.04; Fig. 5C ). On multivariate analysis, VIM-positive CTCs were found to be significantly 
POTENTIAL UTILITY OF HCC CTCs
The value of HCC CTCs and VIM-positive CTCs as biomarkers goes beyond initial prognosis, presenting potential utility for both longitudinal disease monitoring as well as appropriate treatment selection. Eleven patients in the study underwent serial blood draws and CTC enumeration over the course of treatment, with disappearance of CTCs following successful tumor resection and ablation, and a subsequent reappearance of CTCs prior to clinical recurrence (data not shown).
One such example is illustrated in Fig. 6A . The patient was a 63-year-old gentleman with compensated cirrhosis and a 5.8-cm arterially enhancing biopsy-proven HCC. His preresection blood draw revealed 8 VIMpositive CTCs (14 total HCC CTCs). He underwent a partial right hepatectomy, which revealed a 5.8-cm dominant lesion with a subcentimeter satellite lesion with microvascular invasion. CTC enumeration at 1 and 2 months after resection revealed no CTCs, with magnetic resonance imaging (MRI) revealing no evidence of recurrence. However, his third postresection blood draw revealed 6 VIM-positive CTCs (12 HCC CTCs), with a subsequent MRI demonstrating a segment 8 HCC recurrence. The presence of VIM-positive CTCs consistently portended faster TTR following locoregional treatment (Fig. 5D) , with an example illustrated in Fig. 6B . The patient had a solitary 4-cm right hepatic lobe HCC without evidence of metastases, but despite being radiographically staged as an early-stage patient, was found to have 12 VIM-positive CTCs (15 HCC CTCs). Despite successful locoregional therapy with TACE, she was found to have multifocal HCC on her 1-month postprocedure scan with rapid development of metastatic lung nodules at 3 months after the procedure.
Discussion
The limitations of existing clinicopathologic staging systems of HCC is evident in the high recurrence rate following locoregional therapies or curative-intent surgical interventions such as resection or transplantation. CTCs are emerging as a promising biomarker for several cancer types, but their application to HCC has been limited when using existing assays that rely on epithelial cell surface markers alone for CTC capture. In this study, we present the development of a novel multimarker CTC capture platform that allows for the identification, enumeration, and analysis of HCC CTCs with high sensitivity and specificity. Furthermore, we identify a phenotypic subpopulation of VIM-positive CTCs, which are highly associated with advanced or metastatic HCC, increased recurrence after potentially curative therapy, and inferior PFS and OS.
A unique strength of our study was the utilization of a multimarker capture antibody cocktail that allowed for the detection of CTCs across all HCC stages with high sensitivity and specificity. The majority of current CTC enrichment platforms rely on antibodies to the cell surface marker EpCAM alone, potentially limiting their utility in HCC where expression of EpCAM is reported in only 20%-35% of tumors. (8) ASGPR, a transmembrane cell surface protein highly expressed in well-differentiated HCCs, yielded high CTC capture rates in previous HCC studies and was used in our antibody cocktail. (7, 9, 19) On the basis of our TMA studies, we also included GPC-3, because its expression has been associated with the presence of poorly differentiated HCC, (27) arguably the most important subset of tumors to be detected given their poor prognosis. This unique 3-marker antibody cocktail allowed us to detect CTCs from 96.7% of all patients with HCC, compared with 20%-50% captured using EpCAM alone. (6, (28) (29) (30) Arguably our most important finding was the identification of the subpopulation of VIM-positive CTCs and their association with more advanced-stage disease, faster HCC progression, and inferior survival for all patients and the subset of potentially curable patients undergoing locoregional treatments (Fig. 5A,C) . VIM is an intermediate filament ubiquitously expressed in normal mesenchymal cells and is involved in cellular processes including stress resistance and structural integrity. (31) VIM overexpression is widely regarded as the canonical marker of EMT in epithelial cancers, (31) and tumors expressing VIM demonstrate accelerated tumor growth and increased invasiveness. In HCC, VIM overexpression in the primary tumor has been linked to more aggressive tumor biology, inferior survival outcomes, and the establishment of the tumor initiating capacity critical for metastases. (14, 15) LIVER TRANSPLANTATION, Vol. 24, No. 7, 2018 COURT ET AL.
The importance of VIM overexpression in CTCs as a marker of metastatic potential has been established previously in several cancer types, but the utility of VIM for HCC CTCs has only recently been considered. (13, (32) (33) (34) Our finding that VIM-positive CTCs were found almost exclusively in patients with advanced-stage HCC corroborates previous reports in breast and prostate cancer that found the presence of VIM-positive CTCs as a marker of metastatic disease and worse outcomes. (35) Given that CK-positive epithelial cells have been found in the blood of patients with inflammatory gastrointestinal disease such as inflammatory bowel disease and cirrhosis, we feel that the use of additional markers is important to ensure that no benign epithelial cells are being misidentified as CTCs. (36) This is 1 reason that we believe that VIM-positive CTCs may hold more clinical relevance for HCC, where the vast majority of patients have underlying liver cirrhosis. Furthermore, we demonstrated that VIM-positive CTCs vastly outperform the only existing serum biomarker, AFP, for both HCC staging and prognosis (Fig. 4D) . In particular, our finding that VIM-positive CTCs are highly predictive of earlier recurrence and worse survival in otherwise indistinguishable early-stage patients undergoing locoregional or surgical therapy highlights their potential utility as a biomarker for LT candidate selection. Hopefully, the use of VIM-positive CTCs as an adjunct biomarker may help overcome the limitation of existing clinicopathologic staging systems in distinguishing cancer-specific outcomes within the subset of potentially curable patients.
Our study builds upon a number of recent publications highlighting the potential utility of CTCs, and CTC phenotyping in particular. Wang et al. used fluorescent in situ hybridization of mesenchymal and epithelial messenger RNA transcripts in CTCs to demonstrate that the presence of 1 or more mesenchymal CTCs was associated with early recurrence after curative-intent resection. (32) Similarly and using the same CTC capture system, Chen et al. found that CTCs can discriminate between patients with metastatic and nonmetastatic disease, and that significantly more mesenchymal CTCs were found in patients with metastatic disease and higher Barcelona Clinic Liver Cancer (BCLC) stage. (34) These recent studies, along with our current findings, highlight the potential of mesenchymal CTCs, such as VIM-positive CTCs, as a clinical biomarker for patients with HCC that may play an important role in prognostication and treatment selection.
We believe that the value of HCC CTCs as a tool for both longitudinal monitoring of disease and identification of patients with aggressive underlying disease is apparent. Given the ease and repeatability of the noninvasive HCC CTC assay, the reliable serial monitoring of a patient's response to treatment would be possible. In patients undergoing surgical resection and ablation, total HCC CTCs dropped significantly after treatment, but increased in the subset of patients who subsequently proved to have recurrence on follow-up imaging (Fig.  6 ). In addition, VIM-positive CTCs were highly predictive of recurrence and progression in the subset of potentially curable patients undergoing successful locoregional therapy who initially demonstrated no evidence of disease on posttreatment imaging. This highlights the potential role of VIM-positive CTCs for the selection of patients undergoing curative LT, where the identification of patients likely to have poor outcomes is a critical, unmet need to avoid the loss of scarce donor allografts. We plan to further investigate these potential roles with ongoing recruitment, enumeration, and phenotyping of HCC CTCs in early-stage patients undergoing curative intent treatment.
In conclusion, we developed a HCC multimarker antibody-based CTC capture assay that allows for the identification of HCC CTCs as well as a distinct subpopulation of VIM-positive CTCs. We first optimized and validated the assay's functionality for capturing HCC CTCs using both spiked cell line and clinical samples. In a subsequent prospective study of 80 patients (one of the largest HCC CTC studies to date), 61 of whom had HCC, our assay allowed for detection of HCC CTCs from nearly all patients with HCC, with highly accurate discrimination between patients with HCC and those with NMLD or healthy controls. Most importantly, a phenotypic subpopulation of EMT-type, VIM-positive CTCs allowed for accurate discrimination of patients with early-stage, potentially curable HCC from those with advancedstage, incurable disease. The presence of any VIMpositive CTCs was associated with earlier recurrence and inferior PFS in the subset of patients undergoing curative intent locoregional therapy. Our early results indicate that the novel NanoVelcro CTC Assay is effective for HCC CTC capture and phenotyping, with VIM-positive CTCs showing great promise for identifying early-stage patients with occult aggressive disease. Validation of our findings in a larger prospective cohort of patients may allow for the adoption of an HCC CTC assay as an important biomarker in this deadly malignancy.
